Immunogenicity and safety of influenza vaccine in lung cancer patients receiving immune checkpoint inhibitors
- Conditions
- influenza
- Registration Number
- JPRN-UMIN000041923
- Lead Sponsor
- Department of Pulmonology, Kameda Medical Center
- Brief Summary
Influenza vaccination in the 23 patients included in the immunogenicity analyses significantly increased geometric mean titer for all strains, and seroprotection rate, seroresponse rate, and seroconversion rate were 52% to 91%, 26% to 39%, and 26% to 35%, respectively. In the 24 patients included in the safety analyses, 7 (29%) and 5 (21%) patients exhibited systemic and local reactions, respectively. Only one patient (4%) (hypothyroidism, grade 2) showed post-vaccination immune-related adverse events.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 24
Not provided
1 Patients who have been vaccinated with influenza vaccine in the 2020/2021 season 2 Patients who have had anaphylaxis due to the components of influenza vaccine, or those who may have allergies 3 Patients with egg allergies 4 Influenza infected patients in 2020/2021 season 5 Patients who suffered from acute febrile illness or other serious illness at the timing of vaccination 6 Those who received a cytotoxic agent within 1 month of vaccination 7 Those who are taking steroids / immunosuppressants (excluding administration as antiemetics) 8 Others who are not suitable for vaccination
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method